OTC Markets OTCPK - Delayed Quote USD

Novo Nordisk A/S (NONOF)

134.16

-3.39

(-2.46%)

At close: May 31 at 3:51 PM EDT

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

These two drugmakers have a lot more in common than their market-beating potential.

Motley Fool 16 hours ago

NVO

LLY
Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run

Medicare just revised its guidelines to include coverage of Wegovy for patients with cardiovascular complications.

Motley Fool 17 hours ago

NVO
This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

These stocks are trading at sky-high valuations which could make them vulnerable to sell-offs.

Motley Fool yesterday

NVO

LLY
S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly, Novo Nordisk, Vertex Pharmaceuticals, Intuitive Surgical and Universal Health are all trading in or near buy zones. Medical stocks are often viewed as defensive growth stocks, because their growth is insulated from economic swings due to the government or insurance covering most of the costs. Eli Lilly is in a buy zone while weight-loss drug rival and fellow IBD Leaderboard member Novo Nordisk is setting up.

Investor's Business Daily yesterday

NVO

LLY

VRTX
The ‘hardcore’ scientists shifting the dial on obesity

When Nadeem Sarwar got a call asking him to work on stopping people becoming obese, he was “quite confused”.

The Telegraph yesterday

NVO
Netflix Stock Faces Test Of Time As IBD 50 Oil Stock Nears 10-Bagger Status

As a stock's advance gets long in the tooth, shares may still form bases, but late-stage formations carry risks. Netflix stock and Novo Nordisk, two IBD 50 growth stocks, are in late-stage bases. The fourth or fifth bases in a long-term advance are more prone to failure than earlier patterns, mainly because it gets harder to extend gains the longer that shares keep rising.

Investor's Business Daily 2 days ago

NFLX

NVO
Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?

Novo Nordisk stock traded close to a buy point Friday afternoon as shares bounced from their 21-day line this week.

Investor's Business Daily 2 days ago

NVO
Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030

(Bloomberg) -- Goldman Sachs Group Inc. sees growing potential for the global market for weight-loss drugs by the end of the decade.Most Read from BloombergWall Street Billionaires Are Rushing to Back Trump, Verdict Be DamnedDonald Trump Becomes First Former US President Guilty of CrimesTrump Is Guilty on All Counts in Hush-Money Case. Now What?South Africa Election Results With 29% Voting Districts InFed’s Favored Inflation Gauge Cools, Spending Unexpectedly DropsThe obesity market — currently

Bloomberg 2 days ago

LLY

NVO
Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'

GLP-1 medication supply constraints have left many patients grappling with the challenge of accessing these highly sought-after drugs. Ro CEO Zach Reitano joins Asking for a Trend to shed light on how his company aims to make supply information more readily available to patients in need. Reitano underscores Ro's core mission of "building goal-oriented healthcare" tailored to the individual needs of its patients. Recently, the company has been dedicating its efforts to addressing obesity, but they have also recognized "a massive shortage" in the availability of GLP-1 drugs. Consequently, Ro has been proactively "building products and services to help patients navigate and manage through these supply challenges." Reitano characterizes the current US healthcare landscape as "one of one," noting that "never before in healthcare has the majority of the US population been eligible for a drug." This situation has led to patients and providers "desperately" wanting access to these therapies, resulting in severe supply-demand dynamics, a challenge Reitano believes could persist for years to come. Reitano explains Ro's goal is to "crowdsource" supply information with its tracker, streamlining the process of accessing these drugs for both patients and healthcare providers. For more expert insight and the latest market action, click here to watch this full episode of Asking for a Trend. This post was written by Angel Smith

Yahoo Finance Video 3 days ago

NONOF
-2.46%
NVO

LLY
Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks 3 days ago

NVO
Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?

Eli Lilly stock broke out after the company reported positive results for Crohn's disease drug. Is LLY stock a buy right now?

Investor's Business Daily 3 days ago

LLY

NVO

BIIB
Goldman Sachs Says Buy European Pharma Stocks Touting Innovation

(Bloomberg) -- European drugmakers that are focused on building portfolios of new medicines have gotten a nod from analysts at Goldman Sachs Group Inc.Most Read from BloombergWorld’s Largest Nuclear Plant Sits Idle While Energy Needs Soar‘Not Gonna Be Pretty:’ Covid-Era Homebuyers Face Huge Rate JumpWarning Signals Are Flashing for Homeowners in Texas and FloridaInsurers Sink as UnitedHealth Sees ‘Disturbance’ in MedicaidAmerican Air Fired Commercial Head After Sales Strategy Alienated Corporate

Bloomberg 3 days ago

AZN

NVO
Nvidia, advances in cancer research, climate change under Trump: Market Domination

Nvidia (NVDA) continues to dominate the tech sector as the company's shares move past $1,100. The chip giant earned a boost from Elon Musk, who announced that xAI's supercomputer will run on Nvidia technology. Meanwhile, Tesla (TSLA) shareholders are awaiting an important vote on June 13, which will dictate the fate of Musk's proposed pay package of $56 billion. The American Society of Clinical Oncology (ASCO) will hold its annual meeting in Chicago this week, exploring the latest advancements in the cancer research sector. Tom Steyer, Galvanize Climate Solutions Co-Executive Chair, also joins the show to give insight into the state of climate change mitigation under a possible second Trump presidency. For more expert insight and the latest market action, click here.

Yahoo Finance Video 5 days ago

NVDA

TSLA

AMGN
Sector Update: Health Care Stocks Fall Late Afternoon

Sector Update: Health Care Stocks Fall Late Afternoon

PREMIUM
MT Newswires 5 days ago

JNJ

NVO
SSE-backed wind farm fined record £33m for pushing up household bills

A wind farm owned by energy giant SSE is to pay a record fine to the energy regulator after overcharging customers.

The Telegraph 5 days ago

NWG

^FTSE

^GSPC
Sector Update: Health Care Stocks Retreat Tuesday Afternoon

Sector Update: Health Care Stocks Retreat Tuesday Afternoon

PREMIUM
MT Newswires 5 days ago

JNJ

NVO
Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System

Novo Nordisk A/S (NYSE:NVO) has disclosed that it retains approximately 60% of the list price of its diabetes and obesity medications, Ozempic and Wegovy, in the U.S. after accounting for rebates and fees paid to intermediaries. This revelation comes amid intensifying scrutiny over the cost of these blockbuster drugs. In a recent letter to Senator Bernie Sanders, the European drug maker expressed willingness to collaborate with lawmakers to tackle systemic issues hindering patients’ access to me

Benzinga 5 days ago

NVO
Dow Jones Tech Giant Apple, AI Leader CrowdStrike Eye Buy Points

Dow Jones tech giant Apple stock and AI Leader CrowdStrike are approaching new buy points in today's stock market.

Investor's Business Daily 5 days ago

CRWD

AAPL

^DJI
Market Chatter: Novo Nordisk Tells US Senate Health Committee Chair Sanders It Only Keeps 60% of Ozempic, Wegovy List Price

Market Chatter: Novo Nordisk Tells US Senate Health Committee Chair Sanders It Only Keeps 60% of Ozempic, Wegovy List Price

PREMIUM
MT Newswires 5 days ago

NVO
Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Zacks 5 days ago

NVO

Performance Overview

Return	NONOF	OMX Copenhagen 25 Index
YTD	+31.84%	+8.84%
1-Year	+70.04%	+9.02%
3-Year	+243.14%	+9.76%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Novo Nordisk A/S (NONOF)

Prediction: These Could Be the Best-Performing Pharmaceutical Stocks Through 2030

Ozempic and Wegovy Are Fueling Novo Nordisk's Business, but Something Else May Be an Even Bigger Growth Driver in the Long Run

This Is the Biggest Risk for Eli Lilly and Novo Nordisk Investors

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

The ‘hardcore’ scientists shifting the dial on obesity

Netflix Stock Faces Test Of Time As IBD 50 Oil Stock Nears 10-Bagger Status

Ozempic Maker Novo Nordisk Stock Up More Than 31% In 2024, But Is It Too Late To Buy Shares?

Goldman Sees Obesity-Drug Market Growing to $130 Billion by 2030

Ro CEO on GLP-1 drug shortage: US healthcare is '1 of 1'

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Is Eli Lilly Stock A Buy On A Recent Crohn's Disease-Related Rally?

Goldman Sachs Says Buy European Pharma Stocks Touting Innovation

Nvidia, advances in cancer research, climate change under Trump: Market Domination

Sector Update: Health Care Stocks Fall Late Afternoon

SSE-backed wind farm fined record £33m for pushing up household bills

Sector Update: Health Care Stocks Retreat Tuesday Afternoon

Novo Nordisk Faces Scrutiny Over High Prices of Ozempic And Wegovy, Blames US Health System

Dow Jones Tech Giant Apple, AI Leader CrowdStrike Eye Buy Points

Market Chatter: Novo Nordisk Tells US Senate Health Committee Chair Sanders It Only Keeps 60% of Ozempic, Wegovy List Price

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

Performance Overview